Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03080974 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
A Phase 2 study of Pancreatic Adenocarcinoma, sponsored by University of Louisville.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03080974: Recruiting Phase 2 study of Pancreatic Adenocarcinoma, sponsored by University of Louisville.
NCT03080974 is a Phase 2 study of Pancreatic Adenocarcinoma that is actively recruiting participants, run by University of Louisville. The registered enrollment target is 10 participants, below the 99,465-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03080974, a Phase 2 study of Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by University of Louisville.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
Primary Outcome
Adverse events and Serious adverse events will be collected
Conditions Studied
Interventions
- DRUG Nivolumab
- PROCEDURE Irreversible Electroporation
Study Locations (1)
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2029-04-01 |
| Phase | Phase 2 |
What NCT03080974 shows while recruiting
NCT03080974 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 99,465-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03080974 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT03080974 about?
NCT03080974 is a clinical study titled "Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma". Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
What is the current status of trial NCT03080974?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-08-14. Estimated completion is 2029-04-01.
What conditions does trial NCT03080974 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT03080974?
The interventions under investigation include: Nivolumab (DRUG), Irreversible Electroporation (PROCEDURE).
Who is sponsoring clinical trial NCT03080974?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03080974 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03080974's enrollment target sits among peer trials
10 60th of 62 higher than 2 of 62 other Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
RECRUITING · Phase 2
-
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
RECRUITING · Phase 2
-
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
-
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI